Prof. dr Mirjana Gotić

hematologist

Prof. dr Mirjana Gotić

Education:

  • 1977-1983 Doctor of Medicine, Faculty of Medicine, University of Belgrade
  • 1984-1988 Postgraduate studies in Hematology, Faculty of Medicine, University of Belgrade
  • 1990 Academic Hematology and Cytogentics, Royal Marsden Hospital, London, (Head Prof. Dr. Daniel Catovsky), Scholarship of the Ministry of Science, Republic of Serbia
  • 1988 – 1992 Specialization in Internal Medicine, Institute of Hematology, University Clinical Center, Belgrade

Academic career:

  • 1989 Master of Medical Sciences (Mr sci med), Faculty of Medicine, University of Belgrade
  • 1991-1999 Assistant at the Department of Internal Medicine, n.b. Department of Hematology, Faculty of Medicine, University of Belgrade
  • June 1998 Doctor of Medical Sciences (Dr sci med), Faculty of Medicine, University of Belgrade
  • 1999-2004 Docent at the Department of Internal Medicine, n.b. Department of Hematology, Faculty of Medicine, University of Belgrade
  • 2004–2011 Associate Professor at the Department of Internal Medicine, n.b. Hematology Clinic, Faculty of Medicine, University of Belgrade
  • from 2011 Professor at the Department of Internal Medicine, n.b. Clinical Professor of Hematology, Faculty of Medicine, University of Belgrade

Work experience:

  • 1986 – 1992 Doctor of Medicine, Institute of Hematology, University Clinical Center, Belgrade
  • 1992 – 2024 Specialist in Internal Medicine, Institute (Clinic) of Hematology, Clinical Center of Serbia, Belgrade
  • 2008 – 2024 Subspecialist in Hematology, Clinic of Hematology, Clinical Center of Serbia, Belgrade
  • 2001- 2022 Head of the Polyclinic-Diagnostic Department of the Hematology Clinic of the Clinical Center of Serbia, Belgrade
  • 2022 – 2024 Head of the Department for Myeloproliferative Neoplasms of the Hematology Clinic of the University Clinical Center of Serbia in Belgrade

 

Memberships:

  • since 1983 Member of the Serbian Medical Association
  • Member of the European Hematology Association since 1994
  • 2002 – 2005 Member of the editorial board of “The Journal of the Hellenic Society of Haematology”
  • since 2009 Member of the Central European Myeloproliferative Study Organization (CEMPO)
  • since 2011 Member of the Editorial Board of the magazine “Serbian Archive for the entire medicine of SLD”
  • 2011-2014 President of the Hematology Section of the SLD
  • 2016-2022 Associate member of the Academy of Medical Sciences of the Serbian Medical Association
  • from 2022 Regular member of the Academy of Medical Sciences of the Serbian Medical Association

National research projects:

2002-2005 MNTR project, no. 1682, entitled: “Molecular-biological detection of minimal residual disease in chronic lymphoid leukemias and its impact on patient survival”, Project leader Prof. Dr. Mirjana Gotić

2006 – 2010 Project MNTR, no. 145048, under the title: “Cellular and molecular mechanisms of hematopoiesis regulation” Project leader Prof. Dr. Pavle Milenković, Associate Researcher Prof. Dr. Mirjana Gotić

2011 – 2022 Project MNTR, no. 175053, under the title: “Investigation of the pathogenesis of hematological malignancies”, Project leader Scientific associate Dr. sci med Vladan Čokić, Ph.D. Research associate Prof. Dr. Mirjana Goti

International research projects and studies:

1992-1997 „An open protocol for the use of Agrelin (Anagrelide) for patients with  thrombocythemia“, Project No 282, Protocol No 292-024 COINVESTIGATOR

1989-1992 „Pentostatin in Patients with Active Hairy Cell Leukemia Previously Treated with Interferon Alpha” Protocol No 188-0015, Group C Treatment Protocol, COINVESTIGATOR

2003-2003 „SPD422-306 ANAGRELIDE RETROSPECTIVE DATA COLLECTION STUDY“, PRINCIPLE  INVESTIGATOR

2003-2005 „A phase III study to evaluate the efficacy and safety of front line therapy with alemtuzumab (Campath, MabCampath) vs chlorambucil in patients with progressive B-cell chronic lymphocytic leukaemia, CAM307“, INVESTIGATOR

2005-2007 „A single blind, multi-centre, randomised multinational Phase III Study to compare the efficacy and tolerability of Anagrelide vs Hydroxyurea in patients with essential thrombocythemia, ANAHYDRET², PRINCIPLE INVESTIGATOR

2006-2007 Study group Indolent Lymphomas: “Therapy Optimization Study for the Treatment of Hairy Cell Leukemia, Subcutaneous Use of Cladribine in Hairy Cell Leukemia”, INVESTIGATOR

2007-2008 “A Phase II, open-label, multicentre, pharmacokinetic, pharmacodynamics and safety study of anagrelide hydrochloride in young (18-50 years) and elderly (³ 65 years) patients with essential thrombocythaemia, SPD422-203“, PRINCIPLE INVESTIGATOR

2007- 2008 “A Phase II trial to evaluate the efficacy and safety of subcutaneously administered alemtuzumab (CAMPATHâ, MabCampathâ) in patients with previously treated B-cell Chronic Lymphocytic Leukaemia, CAM203“, INVESTIGATOR

2007 – 2010 “A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients, SPD422-403“, PRINCIPLE INVESTIGATOR for Serbia

2009 – 2016 COORDINATING PRINCIPLE INVESTIGATOR for European Union and Eastern Europe

2012 – 2014 „A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects with Relapsed and Refractory Multiple Myeloma, PX-171-011“, PRINCIPLE INVESTIGATOR

2016 -2017 ‘A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia,  CD-ON-CAT-8015-1053“,  PRINCIPLE INVESTIGATOR

From 2021 “A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician¢s Choice on Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/mL), PACIFICA, PAC303“, PRINCIPLE INVESTIGATOR

2021-2023 „An Open –Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and KRT-232 in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis, KRT-232-113“,  PRINCIPLE INVESTIGATOR

Awards and publications:

2018 Award for scientific and research work of the Serbian Medical Society

Number of presented and published works: > 400

(90 papers “in extenso” in the Pub Med database)

Number of citations (Google Academic): 1707

h-index: 19

 

Hematologists